Source link : https://www.newshealth.biz/health-news/bdmards-prevent-esrd-in-most-patients-with-aa-amyloidosis/
TOPLINE: Treatment with biologic disease-modifying antirheumatic drugs (bDMARDs), particularly tocilizumab, can suppress inflammation and preserve renal function in a majority of patients with chronic inflammatory disorders who develop serum amyloid alpha (SAA) amyloidosis. METHODOLOGY: AA amyloidosis, characterized by the misfolding of the SAA protein, is observed in patients with inflammatory diseases and can lead to […]
Author : News Health
Publish date : 2024-05-10 07:06:50
Copyright for syndicated content belongs to the linked Source.